PRMT9 and acute myeloid leukemia: Specifically, our approach targets the arginine methyltransferase PRMT9 to ablate AML LSCs by downregulating the synthesis of short-lived oncoproteins; targeting PRMT9 also induces DNA damage-mediated activation of cGAS and release of cGAMP, thereby cross-priming T cells via a type I IFN response.